Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/bjh.17664 http://scihub22266oqcxt.onion/10.1111/bjh.17664 34114204!ä!34114204 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Br+J+Haematol 2021 ; 194 (3): 518-529 Nephropedia Template TP {{tp|p=34114204|t=2021. COVID-19 and immunothrombosis: emerging understanding and clinical management |pdf=|usr=}}{{34114204}} gab.com Text COVID-19 and immunothrombosis: emerging understanding and clinical management JO: Br J Haematol http://www.kidney.de/pget.php?&tw=1&pmid=34114204 #FOAvip The COVID-19 pandemic has been the most significant health crisis in recent global history. Early studies from Wuhan highlighted COVID-19-associated coagulopathy and a significant association with mortality was soon recognised. As research continues across the world, more evidence is emerging of the cross-talk between the innate immune system, coagulation activation and inflammation. Immunothrombosis has been demonstrated to play a key role in the pathophysiology of severe COVID-19, with extracellular histones and neutrophil extracellular traps detected in the plasma and cardiopulmonary tissues of critically ill patients. Targeting the components of immunothrombosis is becoming an important factor in the treatment of patients with COVID-19 infection. Recent studies report outcomes of intermediate and therapeutic anticoagulation in hospitalised patients with varying severities of COVID-19 disease, including optimal dosing and associated bleeding risks. Immunomodulatory therapies, including corticosteroids and IL-6 receptor antagonists, have been demonstrated to significantly reduce mortality in COVID-19 patients. As the pandemic continues, more studies are required to understand the driving factors and upstream mechanisms for coagulopathy and immunothrombosis in COVID-19, and thus potentially develop more targeted therapies for SARS-CoV-2 infection, both in the acute phase and in those who develop longer-term symptom burden. Twit Text FOAVip COVID-19 and immunothrombosis: emerging understanding and clinical management ????Br J Haematol http://www.kidney.de/pget.php?&tw=1&pmid=34114204 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34114204 #FOAvip English Wikipedia <ref>{{Cite pmid|34114204}}</ref> COVID-19 and immunothrombosis: emerging understanding and clinical management #MMPMID34114204 Shaw RJ; Bradbury C; Abrams ST; Wang G; Toh CH Br J Haematol 2021[Aug]; 194 (3): 518-529 PMID34114204show ga The COVID-19 pandemic has been the most significant health crisis in recent global history. Early studies from Wuhan highlighted COVID-19-associated coagulopathy and a significant association with mortality was soon recognised. As research continues across the world, more evidence is emerging of the cross-talk between the innate immune system, coagulation activation and inflammation. Immunothrombosis has been demonstrated to play a key role in the pathophysiology of severe COVID-19, with extracellular histones and neutrophil extracellular traps detected in the plasma and cardiopulmonary tissues of critically ill patients. Targeting the components of immunothrombosis is becoming an important factor in the treatment of patients with COVID-19 infection. Recent studies report outcomes of intermediate and therapeutic anticoagulation in hospitalised patients with varying severities of COVID-19 disease, including optimal dosing and associated bleeding risks. Immunomodulatory therapies, including corticosteroids and IL-6 receptor antagonists, have been demonstrated to significantly reduce mortality in COVID-19 patients. As the pandemic continues, more studies are required to understand the driving factors and upstream mechanisms for coagulopathy and immunothrombosis in COVID-19, and thus potentially develop more targeted therapies for SARS-CoV-2 infection, both in the acute phase and in those who develop longer-term symptom burden. |Animals[MESH] |Blood Coagulation[MESH] |COVID-19/blood/*complications/immunology/therapy[MESH] |Disease Management[MESH] |Humans[MESH] |Immunogenic Cell Death[MESH] |Inflammation/blood/etiology/immunology/therapy[MESH] |SARS-CoV-2/immunology[MESH]COVID-19 and immunothrombosis: emerging understanding and clinical man(epmc).pdf DeepDyve Pubget Overpricing